<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13376">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028507</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2013-02</org_study_id>
    <secondary_id>2013-003170-27</secondary_id>
    <nct_id>NCT02028507</nct_id>
  </id_info>
  <brief_title>Phase III Study of Palbociclib (PD-0332991) in Combination With Exemestane Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Non-steroidal Aromatase Inhibitors</brief_title>
  <acronym>PEARL</acronym>
  <official_title>Phase III Study of Palbociclib (PD-0332991) in Combination With Exemestane Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Non-steroidal Aromatase Inhibitors (PEARL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, multicenter, open label, controlled, randomized phase III study
      comparing the efficacy and safety of palbociclib in combination with exemestane versus
      capecitabine in postmenopausal women with HR positive/HER2 negative MBC whose disease was
      refractory to previous non-steroidal aromatase inhibitors (NSAI: letrozole or anastrozole),
      defined as recurrence while on or within 12 months after the end of adjuvant treatment or
      progression while on or within 1 month after the end of treatment for advanced disease. It
      is not mandatory to have letrozole or anastrozole as the most recent treatment before
      randomization but progression while receiving the most recent systemic therapy had to be
      documented before randomization. Patients must have measurable disease or lytic bone lesions
      in the absence of measurable disease. Approximately 348 patients will be randomized 1:1
      between the experimental arm (Arm A: approximately 174 patients treated with palbociclib
      plus exemestane) and the control arm (Arm B: approximately 174 patients treated with
      capecitabine).

      The study hypothesis is to demonstrate that palbociclib in combination with exemestane is
      superior to capecitabine in prolonging Progression-Free Survival (PFS) in postmenopausal
      women with HR positive/HER2 negative MBC whose disease was resistant to non-steroidal
      aromatase inhibitors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS).</measure>
    <time_frame>Approximately 36 months from the start of study randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Complete Response (CR) plus Partial Response (PR) divided by the number of patients randomized with measurable disease</measure>
    <time_frame>Approximately 36 months from the start of study randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR): CR plus PR plus stable disease lasting more than 24 weeks divided by all randomized patients (ITT population).</measure>
    <time_frame>Approximately 36 months from the start of study randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration (RD) (RD)</measure>
    <time_frame>Approximately 36 months from the start of study randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS).</measure>
    <time_frame>Approximately 36 months from the start of study randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year and 2 year survival probabilities</measure>
    <time_frame>1 year and 2 year after patient inclusion at the trial</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Day 1 of each cycle.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be assessed by standard clinical and laboratory tests (hematology, serum chemistry). Adverse events grade will be defined by the NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Palbociclib plus Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib, 125 mg, orally once daily on Day 1 to Day 21 followed by 7 days off treatment given as every 28 days cycles in combination with Exemestane, 25 mg, orally once daily (continuously).
NOTE: In patients within the PK sub-study, exemestane will be administered daily during a 7-day lead-in period (day minus-7 through day minus-1) immediately preceding cycle 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine can be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <arm_group_label>Palbociclib plus Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <arm_group_label>Palbociclib plus Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient has signed the informed consent document.

          2. Females with histologically confirmed MBC whose disease is resistant to previous
             nonsteroidal aromatase inhibitors (letrozole or anastrozole), defined as: Recurrence
             while on or within 12 months after the end of adjuvant treatment with NSAI or
             Progression while on or within 1 month after the end of treatment with NSAI for
             advanced disease.

          3. Previous chemotherapy is permitted either in the (neo) adjuvant setting and/or first
             line therapy for MBC.

          4. It is not mandatory to have letrozole or anastrozole as the most recent treatment
             before randomization but progression of the MBC documented during receipt of the most
             recent systemic therapy before randomization should be documented.

          5. Hormonal receptor positive (HR+) breast cancer based on local laboratory
             determination. HR+ defined as major or equal to 1 percent positive cells by IHC for
             ER and/or PgR.

          6. Documented HER2 negative breast cancer based on local laboratory determination on
             most recent tumor biopsy. HER2 negative tumor is determined as IHC score 0 or 1+ or
             negative by ISH (FISH/CISH/SISH) defined as a HER2/CEP17 ratio minor to 2 or for
             single probe assessment a HER2 copy number minor to 4.

          7. Measurable disease or lytic bone lesions in the absence of measurable disease
             according to RECIST 1.1 criteria.

          8. Patient is at least 18 years of age.

          9. Eastern Cooperative Oncology Group (ECOG) Performance Status minor or equal to 1.

         10. Life expectancy major or equal to 12 weeks.

         11. Adequate organ and bone marrow function

         12. Postmenopausal women defined as women with: Prior bilateral surgical oophorectomy, or
             Medically confirmed post-menopausal status defined as spontaneous cessation of
             regular menses for at least 12 consecutive months with no alternative pathological or
             physiological cause.

         13. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical
             procedures to NCI CTCAE version 4.0 Grade minor or equal to 1 (except alopecia or
             other toxicities not considered a safety risk for the patient at investigator´s
             discretion).

         14. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
             tests and other study procedures.

        Exclusion Criteria:

          1. Have received more than 1 prior chemotherapy regimen for MBC. NOTE: Other previous
             anticancer endocrine treatments for advanced disease are allowed.

          2. Patients with advanced, symptomatic, visceral spread that are at risk of
             life-threatening complications in the short term (including patients with massive
             uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis and
             over 50% liver involvement).

          3. Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis or
             leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or
             progressive growth. Patients with a history of CNS metastases or cord compression are
             eligible if they have been definitively treated with local therapy (eg,
             radiotherapy,) and are clinically stable off anticonvulsants and steroids for at
             least 4 weeks before randomization.

          4. Prior treatment with any CDK4/6, mTOR or PI3K inhibitor (any agent whose mechanism of
             action is to inhibit the PI3 kinase-mTOR pathway) or capecitabine.

          5. Prior treatment with exemestane in the metastatic setting. If the patient has
             received exemestane in the adjuvant setting and developed MBC, she will be eligible
             for the study provided:

               -  She has received letrozole/anastrozole as first-line MBC and progressed.

               -  At least 1 year has elapsed since the end of adjuvant exemestane treatment.

          6. Patients treated within the last 7 days prior to randomization with:

               -  Food or drugs that are known to be CYP3A4 inhibitors

               -  Drugs that are known to be CYP3A4 inducers

               -  Drugs that are known to prolong the QT interval

          7. Major surgery, chemotherapy, radiotherapy, any investigational agent or other
             anti-cáncer therapy within 4 weeks before randomization. Patients who received prior
             radiotherapy to more or equal 25 percent of bone marrow are not eligible independent
             of when it was received.

          8. Diagnosis of any other malignancy within 3 years prior to randomization, except for
             adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of
             the cervix.

          9. QTc major 480msec (based on the mean value of the triplicate ECGs), family or
             personal history of long or short QT syndrome, Brugada syndrome or known history of
             QTc prolongation, or Torsade de Pointes (TdP).

         10. Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging
             drug (eg, hypocalcemia, hypokalemia, hypomagnesemia).

         11. Any of the following within 6 months of randomization: myocardial infarction,
             severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 Grade
             major or equal to 2, atrial fibrillation of any grade, coronary/peripheral artery
             bypass graft, symptomatic congestive heart failure, cerebrovascular accident
             including transient ischemic attack, or symptomatic pulmonary embolism.

         12. Difficulties to swallow tablets, malabsorption syndrome disease significantly
             affecting gastrointestinal function, resection of the stomach or small bowel, or
             active inflammatory bowel disease or chronic diarrhea.

         13. Known hypersensitivity to exemestane, palbociclib, capecitabine or any of their
             excipients.

         14. Any of the following contraindications for chemotherapy with capecitabine:

               -  Known deficiency or family history of deficiency of dihydropyrimidine
                  dehydrogenase.

               -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or
                  chemically related analogues, such as brivudine.

         15. Known human immunodeficiency virus infection.

         16. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the patient
             inappropriate for entry into this study.

         17. Recent or active suicidal ideation or behavior
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Martin, MD, PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Carrasco, MD</last_name>
    <phone>+ 34 916 59 28 70</phone>
    <email>evacarrasco@geicam.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Juan Rafael De La Haba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <state>Andalucia</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pedro Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen De La Victoria</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emilio Alba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuel Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragon</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Anton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Zaragoza Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragon</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laura Murillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalaio Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <state>Castilla La Mancha</state>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Encarna Adrover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen De La Salud</name>
      <address>
        <city>Toledo</city>
        <state>Castilla La Mancha</state>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Ignacio Chacon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Sonsoles</name>
      <address>
        <city>Avila</city>
        <state>Castilla y Leon</state>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Enrique Ales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cesar Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Margeli Vila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xavier Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO de L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat-Barcelona</city>
        <state>Cataluña</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Miguel Gil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de lleida</name>
      <address>
        <city>Lleida</city>
        <state>Cataluña</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Serafin Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Begoña Bermejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana Santaballa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <state>Extremadura</state>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Santiago Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lourdes Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elena Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gran Canarias Dr. Negrin</name>
      <address>
        <city>Las Palmas de Gran Canarias</city>
        <state>Gran Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Jesus Blanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabel Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Angel Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eva Maria Ciruelos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Miguel Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen De La Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Luis Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palbociclib</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Hormonal Receptor positive</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Resistance to non-steroidal Aromatase inhibitors</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
